According to the Goldstein Market Intelligence report , The global diabetes care drugs market reached USD 78.7 billion in 2019 and is anticipated to register a CAGR of 4.8 % during the forecast period.
According to WHO, diabetes prevalence has been rising more rapidly in middle- and low-income countries. It is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation. In 2016, an estimated 1.6 million deaths were directly caused by diabetes. Almost half of all deaths attributable to high blood glucose occur before the age of 70 years. WHO estimates that diabetes was the seventh leading cause of death in 2016.
Report is available at:- https://bit.ly/2KlfmNe

Antidiabetic Drugs Market Segmentation
By Drug Class
• Biguanides (metformin)
• Sulfonylureas (glimepiride)
• Meglitinides (repaglinide)
• Thiazolidinediones (pioglitazone)
• Dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin)
• α-Glucosidase inhibitors (acarbose)
By Mode of Administration
• Oral (eg. oral hypoglycemic)
• Intravenously (eg. insulin and GLP-1 receptor agonists)
By Diabetes Type
• Diabetes Type 1
• Diabetes Type 2
• Other Types
• Genetic defects of the β-cell
• Genetic defects in insulin action
• Endocrinopathies
• Drug- or chemical-induced diabetes
• Infections (congenital rubella, coxsackievirus B, cytomegalovirus, adenovirus, and mumps)
By Drug Type
• Generic
• Branded
Based on Geography
• North America (U.S. & Canada) Antidiabetic Drugs Market
• Latin America (Brazil, Mexico, Argentina & Rest of Latin America) Antidiabetic Drugs Market
• Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE) Antidiabetic Drugs Market
• Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia) Antidiabetic Drugs Market
• Middle East & Africa (GCC, South Africa, North Africa, RoMEA) Antidiabetic Drugs Market

Request for Sample Report at :- https://bit.ly/3amt2lB
Covered in this Global Anti-Diabetic Drugs Industry Outlook 2017-2030 Report are
“Global Anti-Diabetic Drugs Industry Outlook 2030” by Goldstein Market Intelligence contains detailed overview of Global Anti-Diabetic Drugs Industry in terms of market segmentation by analysis basis, therapy type and geography. The Report highlights the competitive outlook of major global players that includes the business strategies, product portfolio, revenue distribution, financial analysis, R&D activities, and investments. The in-depth analysis of Global Anti-Diabetic Drugs Industry report will help the clients to assess their business strategies as per the competitive environment in the market space.
Companies Covered in The Antidiabetic Market Report are:
• Zydus Camila
• Actavis
• Alphapharm
• Andromeda Biotech
• Arisaph
• Astellas Pharma
• AstraZeneca
• Bayer
• Biocon
• Blue Cross
• Bristol-Myers Squibb
• Biogen Idec
• Boehringer Ingelheim
• Boston Therapeutics
• Eli Lilly
• Franco-Indian Pharmaceuticals
• Furiex Pharmaceuticals
• Genentech
• Generex
• Biotechnology Corporation
• GlaxoSmithKline (GSK)
• Johnson & Johnson (J&J)
• Lupin, Merck & Co.
• Mylan
Novartis
• Novo Nordisk
• Pfizer
• Ranbaxy Laboratories
• Roche
• Sanofi
• Sun Pharma

Further, Global Anti-Diabetic Drugs Industry Report encompasses the major trends & opportunities, market dynamics and other growth factors of the market. Global Anti-Diabetic Drugs Industry outlook also comprises of key challenges, risk analysis, BPS analysis, SWOT Analysis and Market Attractiveness. The report also highlights the expert analysis to provide a complete overview of the market including the PESTLE analysis of each region and country.

About Goldstein Market Intelligence
Goldstein Market Intelligence helping businesses to be successful at strategy and take informed decisions to grow the business in future. Goldstein Market Intelligence is one of the leading professional services firms, providing Intelligence Services, Consulting & Advisory and research related services to clients. We, at Goldstein Intelligence Group (GIG) practice works side by side with chief executives and their teams to create effective strategies and secure alignment across the organisation. Goldstein Intelligence Group (GIG), a network of worldwide professional services firms, as a leading group with a strong commitment to establishing itself as a truly global-minded professional firm that can provide professional services across the world.

Contact for more Info:

Dennis Abraham
(Global Sales Head)

UK: +44 7520 644482
Email Us :- [email protected]
www.goldsteinresearch.com